+ More
 News Room
 Contact Us
Home \ + More \ News Room

News & Events


GlySens Incorporated to Discuss Latest Algorithm Advancements at the 11th International Conference on Advanced Technologies & Treatments for Diabetes
Vienna, Austria – February 16, 2018 – GlySens executives will share the latest signal processing advancements on Friday, February 16th, 2018 at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) meeting. These data will be presented in the exhibition hall, during an oral E-poster session at 10:15 am (CET) and likewise the data will be displayed in the viewing area throughout the scientific event. These data demonstrate significant advancements in the Eclipse® ICGM® System capabilities and further validate the scientific foundation of a long-term, implanted continuous glucose sensor.


New Data Suggests Potential Reductions to Current Barriers in Continuous Glucose Monitoring Adoption
San Diego, CA – December 12, 2017 – RESEARCH ARTICLE - RE Engler et al. “Adoption Barriers for Continuous Glucose Monitoring and Their Potential Reduction with a Fully Implanted System: Results from Patient Preference Surveys,” Clinical Diabetes 2017 Nov; cd170053. https://doi.org/10.2337/cd17-0053

GlySens® Incorporated today announced the publication of new data in Clinical Diabetes from two recent patient preference studies, providing further support for a proposed 1-year, fully implanted CGM device, with no skin-attached components, currently in development.
According to the data, adult participants and parents of children with diabetes, most frequently sited four factors when deciding to employ CGM: 1) to...
Read More ›
Clinical trial to Evaluate GlySens Eclipse ICGM System
SAN DIEGO, CA – August 7, 2017 – GlySens® Incorporated today announced another series of successful insertions of the ICGM® Sensor in the FAST Trial. This trial is a feasibility study designed to evaluate advanced sensor algorithms in a limited number of clinical participants. Individuals are enrolling at St. Vincent’s Hospital, in Melbourne Australia, with David O’Neal, MD.
According to the World Health Organization (WHO), an estimated 422M adults worldwide are living with diabetes, accounting for 8.5% of the global population. 1The staggering prevalence marks a significant public health problem with substantial economic burden as well as assorted health complications.
Read More ›
GlySens to Present at the American Diabetes Association 77th Scientific Sessions
SAN DIEGO, CA – June 10, 2017 – GlySens® Incorporated, an early stage medical device company focused on the development and commercialization of the Eclipse® ICGM® System, a fully-implantable and long term, continuous glucose monitoring system, today announced that the company will share interim clinical results at the American Diabetes Association, 77th Scientific Sessions in San Diego, CA.
Joseph Lucisano, PhD., Founder and CTO of GlySens Incorporated, is scheduled to share interim clinical data on Saturday, June 10, 2017 at 11:30am (p.s.t.). Interested parties may also view the poster on Saturday, Sunday, and Monday of the meeting in the poster hall, during viewing hours.
NEW Published Data Shows Feasibility of GlySens ICGM System
SAN DIEGO, CA – January 3, 2017 RESEARCH ARTICLE | JY Lucisano et al. "Glucose Monitoring in Individuals With Diabetes Using a Long-Term Implanted Sensor/Telemetry System and Model," Transactions on Biomedical Engineering, September 2017: Vol. 64, No 9,  DOI: 10.1109/TBME.2016. 2619333

– GlySens® Incorporated today announced the publication of new data in Transactions onBiomedical Engineering, from the development of the ICGM® System; intended for long-term monitoring of subcutaneous tissue glucose in people with diabetes. The ICGM System data closely matched reference blood glucose and finger stick values from all participants. Statistical correlation indicated strong association between the sensor signals and reference glucose values. Therefore long-term glucose monitoring in individuals with diabetes is shown to be feasible with this system and further development continues.
Read More ›


GlySens Incorporated Shares Recent Data and Market Insights of the Long Term, Fully Implantable Glucose Monitoring System
BETHESDA, MD – November 10, 2016 – GlySens Incorporated executives, Bill Markle and Joseph Lucisano, PhD presented separate findings at the 16th annual Diabetes Technology Society meeting. This conference brings together leading scientific researchers and health care professionals from around the world to focus on applying science and new technologies to the fight against diabetes. The presentation entitled “Market Opportunities and Customer Preference Data for a Fully Implanted...
Read More ›
Patient Enrollment and Implantation Procedures Complete for FIGS-2 Trial
SAN DIEGO, CA – October 4, 2016 – GlySens Incorporated today announced the successful implantation of the twentieth human subject participating in the Function of Implanted Glucose Sensor 2 (FIGS-2) trial [Clinicaltrials.gov NCT02345967] for people with diabetes in the United States. The FIGS-2 study is a multi-center, long-term assessment of the Eclipse® ICGM® Sensor. The twentieth participant is an important milestone for the company. “We believe the clinical data will further support our growing confidence...
Read More ›
3931 Sorrento Valley Blvd
Suite 110
San Diego, CA 92121
Ph:  +1 (858) 638-7708
Fax: +1 (858) 638-7727

TechnologyNews RoomCareersContact Us

© 2018 GlySens Incorporated. All Rights Reserved.
GlySens®, Eclipse®, and ICGM® are trademarks of GlySens Incorporated registered in the U.S. Patent and Trademark Office.
 Terms of Use Privacy Policy